“The cannabis industry in the U.S. and Europe is characterized by the lack of uniformity and standardization,” Tamir Gedo, CEO of BOL Pharma, an Israeli developer of cannabinoid pharmaceuticals, told Calcalist in an interview Sunday.

Read more on Calcalist here.